首页> 外文会议>World congress on medical physics and biomedical engineering;International congress of the IUPESM >In Vivo Evaluation of Photofrin II Radiosentisitivity for the Treatment of Adenocarcinoma Tumors in Balb-C Mice using Brachytherapy
【24h】

In Vivo Evaluation of Photofrin II Radiosentisitivity for the Treatment of Adenocarcinoma Tumors in Balb-C Mice using Brachytherapy

机译:使用近距离放射疗法对光敏蛋白II放射敏感性在Balb-C小鼠中治疗腺癌的体内评价

获取原文

摘要

To achieve better outcome in cancer treatment, chemical modifiers (radiosensitizers) are used to increase the efficacy of radiotherapy. The aim of this study was to evaluate the effect of photofrin II radiosensitivity for the treatment of adenocarcinoma tumors in Balb-C mice using the brachytherapy. Spontaneous murine model of breast adenocarsinoma was inoculated in Balb-C mice. The tumor bearing mice were injected with PII photosensitizers at a therapeutic dose (3 mg/kg body weight). 24 hours after the topical injection of the PII, two separate groups of the mice were irradiated with 5 Gy and 10 Gy ionizing radiation. The tumor volume was used as an index to determine the efficiency of photofrin II in comparison with the brachytherapy procedure alone. The results did not indicate any difference between the two groups (with and without the PII) after the brachytherapy. Therefore, contrary to other experiments reported in the literature, it can be concluded that the photofrin II does not act as a radiosensitizer in adenocarsinoma tumors.
机译:为了在癌症治疗中获得更好的结果,化学修饰剂(放射增敏剂)用于提高放射治疗的功效。这项研究的目的是评估使用近距离放射疗法对光敏蛋白II放射敏感性治疗Balb-C小鼠腺癌的效果。在Balb-C小鼠中接种乳腺腺癌的自发鼠模型。给荷瘤小鼠注射治疗剂量(3 mg / kg体重)的PII光敏剂。局部注射PII后24小时,分别用5 Gy和10 Gy电离辐射照射两组小鼠。与单独的近距离放射治疗程序相比,将肿瘤体积用作确定Photofrin II疗效的指标。结果表明,近距离放射治疗后两组(有和没有PII)之间没有任何差异。因此,与文献中报道的其他实验相反,可以得出结论,光敏蛋白II不能在腺癌的肿瘤中充当放射增敏剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号